226 F. Supp. 3d 1032
C.D. Cal.2016Background
- Relator Beverly Brown, a former Celgene sales representative, filed a qui tam FCA suit alleging Celgene promoted Thalomid and Revlimid for off‑label cancer uses and paid kickbacks to induce prescriptions that were submitted to federal/state health programs.
- Thalomid initially FDA‑approved for ENL (1998); cancer indications were limited until 2005–2006. Revlimid received narrow approvals in 2005–2006. Celgene allegedly marketed broadly for oncology well before/after those approvals.
- Brown presents internal marketing plans, salesforce growth, training requiring oncology promotion, and expert statistical evidence linking sales contacts to higher prescribing and hundreds of thousands of off‑label claims submitted to government payors.
- Celgene argues (1) truthful/off‑label promotion is not necessarily illegal or is First Amendment protected, (2) physicians exercise independent judgment, (3) many government programs may reimburse off‑label uses, and (4) payments to physicians were legitimate compensation.
- The court denied summary judgment on most off‑label FCA claims, holding triable issues remain on causation, materiality, and scienter for Medicare claims; granted summary judgment for claims to TRICARE, VA, and certain state Medicaid programs and granted summary judgment on all kickback‑based FCA claims (insufficient evidence of actionable kickbacks).
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Off‑label promotion — causation | Celgene’s systematic off‑label marketing substantially caused physicians to write off‑label prescriptions that were presented to government payors | Physician testimony of independent judgment; legitimate medical reasons for off‑label use; no need to identify individual false claims | Denied — genuine dispute: aggregate circumstantial evidence supports a jury inference of substantial‑factor causation for many Medicare claims |
| Off‑label promotion — falsity (Medicare) | Claims for non‑medically accepted indications are false because Medicare Part D covers only "medically accepted" uses | Medicare contractors have discretion and sometimes pay off‑label claims; presentment does not imply entitlement | Held false as a matter of law for Medicare Part D: statutory/regulatory scheme requires medically accepted indication; summary judgment denied on other elements |
| Off‑label promotion — falsity (other payors) | Same theory applied to Medicaid, TRICARE, VA | Various payors have different coverage rules; some states and programs do reimburse off‑label uses | Granted for TRICARE, VA, Tennessee, Texas, Wisconsin Medicaid; denied as to other Medicaid programs where triable issues exist |
| Materiality & Scienter under FCA | Off‑label non‑disclosure was material to payment decisions and Celgene knew or recklessly disregarded reimbursement rules | CMS sometimes reimbursed off‑label uses; Celgene’s interpretation was reasonable | Materiality and scienter are fact issues for trial as to Medicare; court finds Celgene’s legal position not objectively reasonable and evidence could show it was warned away |
| Anti‑Kickback claims | Celgene paid speakers, paid trials, advisory roles, ghostwriting, and supported co‑pay foundations to induce prescribing | Payments were legitimate, fair‑market‑value, administered via vendors; no evidence payments were intended to induce prescriptions or tied to specific patient recommendations | Granted — plaintiff failed to raise triable issues that payments were unlawful kickbacks or caused false claims |
| Statute of limitations | Brown knew off‑label promotion early; many claims predate limitations period | Brown contends she reasonably relied on Celgene’s assurances and did not discover wrongdoing until 2007 | Denied — triable issue whether Brown discovered actionable facts more than 3 years before filing; some pre‑2004 claims not summarily barred |
Key Cases Cited
- Anderson v. Liberty Lobby, 477 U.S. 242 (summary judgment standard)
- Celotex Corp. v. Catrett, 477 U.S. 317 (summary judgment burdens)
- Hooper v. Lockheed Martin Corp., 688 F.3d 1037 (9th Cir. FCA elements)
- Universal Health Servs., Inc. v. U.S. ex rel. Escobar, 136 S. Ct. 1989 (2016) (implied‑certification and materiality framework under FCA)
- In re Neurontin Mktg. & Sales Practices Litig., 712 F.3d 21 (1st Cir.) (use of aggregate/statistical proof to infer causal link between marketing and prescriptions)
- Safeco Ins. Co. v. Burr, 551 U.S. 47 (2007) (objective‑reasonableness and scienter analysis)